Learn More
THE EMERGENCE OF newly identified fungal pathogens and the reemergence of previously uncommon fungal diseases is primarily related to increases in the numbers of susceptible persons: people with HIV infection, bone marrow and organ transplant recipients, cancer patients being treated with chemotherapy, critically ill persons, and very low birth weight ( <(More)
This report summarizes the clinical trials of the A/USSR/77 (H1N1) influenza vaccines performed in 1978. A total of 2,091 subjects participated in these trials. The results of these clinical trials indicated that two doses of H1N1 viral antigen were necessary to produce serum titers of hemagglutinin-inhibiting (HAI) antibody of greater than 1:40 in 80% or(More)
The effectiveness of immunization against influenza in elderly persons is uncertain. A retrospective cohort study in a New York City nursing home examined the occurrence of pneumonia and its related mortality over three consecutive influenza seasons (Nov 1 through April 30, 1979 to 1980, 1980 to 1981, and 1981 to 1982). Nearly one half of approximately 450(More)
Each year, rotaviruses are responsible for 500,000 physician visits, 50,000 hospitalizations , and 20–40 deaths in the United States [1]. In addition, they are estimated to cause up to 520,000 deaths annually among infants and young children worldwide (i.e., 11400 deaths/day), predominantly in developing nations [2]. The live rotavirus vaccine, named(More)
Tuberculosis is the single leading cause of death from any single infectious agent. A world congress on tuberculosis was held to highlight the problem and to discuss recent scientific advances and global strategies for prevention and control. About one-third of the world population is latently infected with Mycobacterium tuberculosis. Over 8 million new(More)
There is an urgent need for a rotavirus vaccine, because up to 592,000 infants and young children <5 years old die each year from rotavirus diarrhea, predominantly in the developing countries. We have developed a tetravalent human-bovine rotavirus (UK) reassortant vaccine with VP7 (G) specificity for serotypes 1, 2, 3, and 4, which has been shown to be(More)
These studies indicate that the high-risk and normal pediatric populations can be safely and effectively immunized with a two-dose regimen of the influenza A/New Jersey/76 virus vaccine. In addition, the studies have demonstrated important differences between split-product and whole-virus vaccines in the pediatric age group. Furthermore, reactogenicity from(More)